Product Center
"HRK-X® 3" secures another win, successfully winning the bid in Gansu Province!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-03-19
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") achieved another milestone in market access—following its successful bid for the Shanxi Province Non-Immunization Program Vaccine Supplementary Procurement Project, the company's domestically developed first and only trivalent influenza virus subunit vaccine for all populations and full doses (HRK-X® 3) secured a winning bid for the Gansu Province Non-Immunization Program Vaccine Sunshine Procurement Project at a price of 298 yuan per dose. HRK-X® 3 is rapidly unlocking market potential and emerging as a new core growth driver for the company, providing solid support for sustained performance growth in the future.
"HRK-X® 3" secures another win, successfully winning the bid in Gansu Province!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") achieved another milestone in market access—following its successful bid for the Shanxi Province Non-Immunization Program Vaccine Supplementary Procurement Project, the company's domestically developed first and only trivalent influenza virus subunit vaccine for all populations and full doses (HRK-X® 3) secured a winning bid for the Gansu Province Non-Immunization Program Vaccine Sunshine Procurement Project at a price of 298 yuan per dose. HRK-X® 3 is rapidly unlocking market potential and emerging as a new core growth driver for the company, providing solid support for sustained performance growth in the future.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-03-19 11:19
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") achieved another milestone in market access—following its successful bid for the Shanxi Province Non-Immunization Program Vaccine Supplementary Procurement Project, the company's domestically developed first and only trivalent influenza virus subunit vaccine for all populations and full doses (HRK-X® 3) secured a winning bid for the Gansu Province Non-Immunization Program Vaccine Sunshine Procurement Project at a price of 298 yuan per dose. HRK-X® 3 is rapidly unlocking market potential and emerging as a new core growth driver for the company, providing solid support for sustained performance growth in the future.
With the World Health Organization (WHO) officially releasing the recommended seasonal influenza vaccine components for the 2026-2027 Northern Hemisphere, the flu vaccine may usher in the "trivalent era."
With keen industry insight and strong R&D-to-commercialization capabilities, Ab&B Bio strategically positioned itself and maintained a precise pace, bringing the country's first and only trivalent influenza virus subunit vaccine suitable for all populations and dosage ranges. Together with its already marketed quadrivalent influenza virus subunit vaccine, this product forms a dual high-end influenza vaccine defense line ("quadrivalent + trivalent"), seamlessly aligning with policy trends and offering the market a more precise and safer new protection option.
As a third-generation influenza vaccine, HRK-X® 3 extracts only the core antigens (HA/NA) from the virus surface, removes internal viral contaminants, resulting in higher purity, lower adverse reactions, superior safety, and enhanced immune efficacy. Phase III clinical data show that it induces fewer local adverse reactions compared to the control group's split vaccine. Full-dose administration provides stronger immune protection for infants and young children while maintaining excellent safety.
HRK-X® 3 achieves a groundbreaking breakthrough by unifying the 0.5ml dosage for all populations aged 6 months and above, providing equal protection for infants, children, and adults while significantly simplifying the vaccination process. This delivers a more convenient and efficient operational experience for healthcare professionals. Additionally, HRK-X® 3 thoughtfully incorporates a VVM label (vaccine temperature indicator), allowing both medical staff and recipients to visually determine vaccine efficacy at a glance. This strengthens the final visual safeguard for vaccine safety, ensuring every vaccination is more reassuring and worry-free.
Currently, Ab&B Bio is accelerating the market approval process for its trivalent influenza virus subunit vaccine (HRK-X® 3), actively expanding its coverage to ensure the continuous supply of high-quality flu vaccines to more provinces (cities). This effort aims to strengthen public immunity and provide professional, reliable health protection for more families.
Meanwhile, Ab&B Bio collaborated with Watson Hong Kong, leveraging its long-established overseas market resources and mature distribution network to accelerate the global expansion of its trivalent influenza vaccine. This initiative actively addresses diverse global public health needs and provides health protection to more families. The company is fully committed to building a second growth curve, driving sustained performance growth.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
